| Compound | PNC-27 |
|---|---|
| Category | Experimental oncolytic peptide |
| Class | Healing and Anti-Inflammatory Peptides |
| Evidence tier | Preclinical |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
PNC-27 is catalogued here as a experimental oncolytic peptide and graded at the "Preclinical" evidence tier. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
A p53-derived peptide designed to disrupt the MDM2-p53 interaction in cancer cells, causing tumor-selective membrane damage in laboratory studies. It is an experimental oncology research tool.
Mechanism of Action
PNC-27 binds MDM2 in the membranes of cancer cells expressing mutant p53, inducing transmembrane pore formation and rapid cell death while sparing normal cells in vitro.
Research and Evidence
Evidence is limited to cell-culture and xenograft studies. No clinical trials have established safety or efficacy in humans.
Safety and Side Effects
No human safety data; as an experimental cytotoxic-selective peptide, clinical use would require a full oncology development program.
Frequently Asked Questions
What is the evidence tier of PNC-27?
PNC-27 is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
Is PNC-27 an approved medicine?
No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for PNC-27?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for PNC-27 studies. [source]
Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.